{"success":true,"data":{"pressRelease":{"id":"163261","rtpr_id":"nGNX1VBf7f-20261007","ticker":"NTHI","exchange":"NASDAQ","all_tickers":["NTHI"],"title":"NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer","author":"Globe Newswire","published_at":"2026-10-07T13:43:54.131Z","article_body":"DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com)-- For\npatients facing cancer, progress ultimately comes down to a deeply personal\nquestion: Can treatment give them more time?\n\nA series of developments reported during 2026 is providing new reasons for\nhope. From an approved treatment for advanced pancreatic cancer to\npersonalized cancer immunotherapy and encouraging survival observations in\nrecurrent brain cancer, publicly traded companies are advancing different\napproaches to some of medicine’s most difficult challenges. These\ndevelopments span different levels of clinical evidence, from exploratory\nPhase 2 findings to randomized Phase 3 results and an FDA approval. SEC\n(https://www.globenewswire.com/Tracker?data=7s-jarmA_Ez5QyKazHtBQNue0KPvJsjcgkPaMFEYpdGhYrtYQbkLFGg_k98hAKweZurACJzEbelLXXYtZp2R6meE3v8wFOu5wldT6ZLyhfYF1JuZ6eRleRno6NVkJeUHSef7Ghq7VRnir_NZd5Haa1JEk4a_1ni0d-BVvx-QOqs=)\n\n24/7 Market News highlights five advances worth following as the year moves\ninto its final quarter, beginning with NeOnc Technologies Holdings and its\nwork in a particularly difficult treatment setting: aggressive brain cancer\nthat has returned after previous therapy.\n\nNeOnc Technologies Holdings (NASDAQ: NTHI): Encouraging Survival Findings\nWhere Better Options Are Urgently Needed\n\nNeOnc stands out in this group for the challenge it is confronting. Recurrent\nhigh-grade brain cancer remains an exceptionally difficult treatment setting.\nThe National Cancer Institute notes that recurrent central nervous system\ntumors are rarely curable, underscoring the importance of developing\nadditional treatment options. Cancer.gov\n(https://www.globenewswire.com/Tracker?data=woZ_YJ3W05l2TPozdw9Z0xMKkDIBOWEH7z4QoZd1ZJwOFD3Zim2SI7CIwKP00uB5fPOrNuGB7KlNre4N4iXbepNFCweiyVTk0CA8z3wYDRkW5vB_u3Zufmkw8Yxy_ybFrcS4sFu4dll4EwT_SetiFA==)\n\nOn August 12, NeOnc reported that patients in its 24-patient Phase 2a study of\nintranasal NEO100 achieved a median overall survival of 26.09 months.\nEstimated survival was 60.9% at 12 months and 54.1% at 24 months. Importantly,\nsurvival was measured from the first treatment dose following recurrence, not\nfrom the original diagnosis. The study involved patients with recurrent or\nprogressive Grade III and Grade IV IDH1-mutant glioma. SEC\n(https://www.globenewswire.com/Tracker?data=nthbVsIQHagvu_IxQOH8TUnfsTh3GPWJIB9c_N26eDKrbb9SfH_oLKPk7RmNBmNed7Ubd0i75jRULnU9zGi8-MV7LQ0zemhS8RtMhWT6J0UFwKzH1ScMA88BqQplJbn4dCH2yOYzrQECLV8jLlXipK_25v1zJWpBnc2I1DQoJmc=)\n\nThe treatment approach is also distinctive. NEO100 is administered\nintranasally by patients at home and is designed to reach the brain through\npathways that bypass the blood-brain barrier, a major obstacle in brain-cancer\ndrug delivery. NeOnc reported predominantly low-grade adverse events and no\nmajor toxicities in the cohort. SEC\n(https://www.globenewswire.com/Tracker?data=mmvm9bW2Ce3AznPsBegRlYUactxVyPeJ9WIeP0SsBrOZsa7_HxXM3kQtbyijXJmIEeBtqdcYWswfIgSpYiOT1hFgnzcE_9p6hG1VHNWar_ZSzhIsAfUPqX6cpZsqf4jlVFtJmSh0HoZyWkU684vqVcX-UqwBNrzIhY5MqwogFH4=)\n\nThese findings represent an encouraging survival signal, not a randomized\ndemonstration of improved survival. The study had no concurrent control group,\nand progression-free-survival findings varied by assessment method, reaching\nstatistical significance against the historical benchmark under RANO 2.0 but\nnot under the original protocol-specified criteria. NeOnc has outlined plans\nto discuss a registrational development pathway with the FDA. SEC\n(https://www.globenewswire.com/Tracker?data=yqGNul-pMhCBs8yCDr1WZYaj-9DsQi7gScyHVLb00vOsAv4e5qv1qlgo7iBokRG0PdOmhzaHsSoOxxeGVeRwoSiEqJ71aA2Wuq3YeLYW2K9iVWGAy_r1YcI7dnW3qGkrfnUj67ITO_lfCTPRqVE_NCZXCSBxin9yokCY9NqJMKo=)\n\nFor a disease setting where treatment options are limited, the combination of\nobserved survival, reported tolerability and an at-home delivery approach\nmakes NEO100 a development worth following as further clinical evaluation\nproceeds. Cancer.gov\n(https://www.globenewswire.com/Tracker?data=woZ_YJ3W05l2TPozdw9Z09EbR0bt3lzmhxWZDOw5vorwUaLtVrYhfVrq0BYr4cz0RKfbv3WVkup9Kz7RoEDQ28a_wvcSFT7c4rVJLgGHnFVjW-aPx_BwmK3TQP7SR4W3OrXWRCMs2q3ZJjiu3mzleA==)\n\nRevolution Medicines (NASDAQ): A Pancreatic-Cancer Advance That Has Already\nReached Approval\n\nRevolution Medicines delivered one of the year’s clearest examples of\nclinical progress translating into an available treatment. On August 26, the\nFDA approved Rasonque, or daraxonrasib, a targeted therapy for metastatic\npancreatic adenocarcinoma. Revolution Medicines\n(https://www.globenewswire.com/Tracker?data=oxa_ZkHAFof5u5n4B5eLrU1MaUoM0bktNicpJdbaFHI6VUGdSmWkO-shcJ4iiN885OkoLB2Xx_sfwg2kGhRAmGQPPZz4NqMskU_7LaTQUr9ttjqac15SR8-V2zYH03dBaNWiyhbpMrGpZSe6Lw5Vqlmzu78yL4ayLaPYRi1KTL9vmNrA-vYQo0gcoC2oZIkNdaqfwnQWBg7HlwQmKalGz45xuS6VMsafZKr1wP7WoVvaG3BZ0VdPcqm7FRMmi9ze)\n\nIn a randomized study involving 500 previously treated patients, median\noverall survival reached 13.2 months with Rasonque versus 6.7 months with\nstandard chemotherapy. Unlike an uncontrolled survival observation, this\nresult established a benefit against a treatment comparator within the same\ntrial. U.S. Food and Drug Administration\n(https://www.globenewswire.com/Tracker?data=9TmfNoC_E_S8Bs-CtCKLhxiqiqI6GXOq0PsqC-0Xk8QpJ6UcYaXcOA2b-NzwRFBlckxMceHiNAXCKxduwQjbswuSAePMklFugyAsleN346Mcx072RiANukCXPuV47RRInJPTtZr1hooJrTJN1qgS43GvP6-8EYYR6uwdZPbbYh6SrhPMQqqFHvMeG5pGD7eHh5T0tZB64q-Q5FZYBrnARl0BcZjBgXJxiCDLo41oHAJqRcZfrkmw9DfHVC_Xbhor)\n\nThe approval is particularly meaningful in pancreatic cancer, where aggressive\ndisease, late detection and historically limited treatment options have\ncontributed to poor outcomes. It also provides a concrete example of what\nsuccessful clinical development can accomplish: moving a promising approach\nfrom research into patient care. U.S. Food and Drug Administration\n(https://www.globenewswire.com/Tracker?data=9TmfNoC_E_S8Bs-CtCKLhxiqiqI6GXOq0PsqC-0Xk8T0nUNatBs04ooC7fisCq3e1lI2KFPQ0zjUo-mJYVr4IMXUtYmgYCBjBrnK5jrV9_l_-h5Ljwx4eE2JGtnkzeU1JoW6v_K3TREJNf-lH9xzIDTgnY0hqNJtmkvfsUm3ehv25dggSJlhLTTbiQV9822vVCioaITJP96NwbrAXf1XpYik4I7h4lZrHqXTSWRF9yiv_bZzopinCuy0teoH7QvK)\n\nModerna (NASDAQ) and Merck (NYSE): Personalized Cancer Immunotherapy Reaches a\nPhase 3 Milestone\n\nModerna and Merck reported a different kind of advance on August 19: positive\nPhase 3 results for intismeran autogene, an individualized mRNA-based cancer\ntherapy, combined with Keytruda.\n\nThe INTerpath-001 trial demonstrated statistically significant improvements in\nrecurrence-free survival and distant-metastasis-free survival compared with\nKeytruda alone in patients whose high-risk melanoma had been surgically\nremoved. According to the companies, this was the first positive Phase 3\nresult for an individualized neoantigen therapy and an mRNA-based cancer\ntreatment. Merck.com\n(https://www.globenewswire.com/Tracker?data=XN3U8SsHvGUJ2EylR72KY5eat3PLMBHn2voYty86vOGbw7XM9ScwFjzAscTo5osOuy1yUydiwOM3l6uaeF61P3zbV9Af7afVr69jEgDbuDq5Tl_HIST9t0LQPTLHbuda6t4zxBiRdrQgNBgnLfxhM2RWk_KT1scjFDyvyI0VSV-tpUsUEKuYdMzBMbv2BlbRpwfDcl5BMEEVJswPt5Ojpx_GnR5tbmyfTKgHRvEHIZL1_JemFjQFoHmwV6T7wV2jCRF9ttYqfEWOwScR_KcXBBtb3X68lR_lWYjzxfTR__wiWHyaIHiWvZjinZbHR3uIWDVolPGCuJI7TFIMKaOPTg==)\n\nThe approach is designed around the characteristics of an individual\npatient’s tumor. Its promise is not a universal vaccine against cancer, but\na more personalized immune response to the disease. Overall-survival follow-up\ncontinues, while the companies plan to engage regulators regarding potential\nsubmissions. Merck.com\n(https://www.globenewswire.com/Tracker?data=XN3U8SsHvGUJ2EylR72KY7_3nSO69ysanpfc6m42Bk3d7Mo2mCuCn44rjXjTmNwpybdL6pKXzEBryAf3VnV41HNg_OwyKZvkQynR6vfNoV35s90Z35oGgY_GYcEfel0J8Oln1ymk9zWSVQDSuTO7GugOPx7yGjWnUjm6ib7fRb5atz6KT7jfRvmPc1WtAcgw83brolH1jbK3-hD-t_v8WuX7rnIY467r_UihkSlWhYtCuFCYW_-c-zWoqT6PUEAes5Ajs7yj4oiATyYPYtO2huAzX7QV0AvAcY9jcB411M7-vllWaBSN5d6wQPuTI4po8v5pLjAv_jLAo-SSqNz_qw==)\n\nJohnson & Johnson (NYSE): Dual-Target Immunotherapy Delivers Substantial\nMyeloma Results\n\nOn July 23, Johnson & Johnson reported that combining Tecvayli and Talvey in\nthe Phase 3 MonumenTAL-6 trial reduced the relative risk of disease\nprogression or death by 89%, and the relative risk of death by 62%, compared\nwith the study’s standard-treatment options.\n\nThe trial involved patients with relapsed or refractory multiple myeloma who\nhad received one to four prior treatment lines. The combination targets two\ndifferent proteins associated with myeloma cells, BCMA and GPRC5D, directing\nimmune activity against the disease through complementary targets. JNJ.com\n(https://www.globenewswire.com/Tracker?data=ixRqyWnoaemxtBuH52lRUFsXADDaHrjzolp4JgbSAIne71lM_I2KnECfRNo2I6GlBwxCmH9Rt2mVY_dSZriwWJDdrtQy6W2yqma1I2J6dgc62ZD74r9hiVrKV5PQnhWxxi-Wa-AyXpDSDqkzjmPnHWQKzzwd7HrpK1qR7THB04I-52mvbx85eqL4uPKJkiULX2Dm9GXrusI_s_FC5Vh2HpNUeFB7QLOqtHHl0s5GHRerp8wy6EE8XjoUy-KwjeQJodL5x6qSAEW-HjXpNSil_Nmn9o1SDNVD2ipBwmTTLJgngTBiZPFen5JwUPUn5bpO)\n\nThe investigational combination’s improvements in both disease control and\noverall survival support the potential to bring this dual-target approach\nearlier into treatment. The reported percentages describe relative reductions\nin risk, not percentages of patients cured. JNJ.com\n(https://www.globenewswire.com/Tracker?data=ixRqyWnoaemxtBuH52lRUFpBWAIdX_TnlPlVKlQWWqXuYoSwteM2i9ACY2PCHMNSxa4DeL_S-78w_yoIckGh-9rYLOqI7wTG2AWPxJ5DgorLmh7aVlXUYr1mWGKBTcjL_Gjg3YDB8k6B1My2x_ncVcFZQPeggnyPe504vKM3jNGIok7iH3O9z_aA1TnjZhvD_N_dUt04kO_X1dj80fRxrtRgqQAlceM0zDDnOpVf9ZnbLeEyW7An4g7ZTk0ivxkJYk-JxCvPo-q4oXzzv-4qpL8Bm0apZgvUfAgsrqicwv4ymSZ0y7assGjxvMSn24SI)\n\nGenmab (NASDAQ) and AbbVie (NYSE): New Hope in First-Line Aggressive Lymphoma\n\nOn October 5, Genmab and AbbVie announced that adding epcoritamab to the\nstandard R-CHOP regimen reduced the relative risk of progression or death by\n51% in the Phase 3 EPCORE DLBCL-2 trial.\n\nThe reported result applied to newly diagnosed diffuse large B-cell lymphoma\npatients with International Prognostic Index scores of 2–5. Its importance\nlies in the possibility of improving treatment at the outset, rather than\nwaiting until the disease returns. AbbVie News Center\n(https://www.globenewswire.com/Tracker?data=UnydQnZmVi-wfDmXlFqz9IKQMehaIH5-KDCh5HG-mkYlecSqWB-2xInn_mEOg0F-wxPanSm7blZs6sEpccewDnkJQZmnRVoP5qdEg78W_5bZckv20Hh5iFtqDwNaR-Bzq7aJQMW4KdfPD4WMDEY3Q0VGmsnP8ZhqtHsjslMHUo1QnbdVGA0HBXEX_QJjoppFQmOnH-XaomC5LL3Urn-aGK4VSbFAYaAJnZoFm3XVIxCPLMbUItCa4nmPQvrAqtOLEGyzF8epaXJ6rrNfyxTxCg84T8MD8fmARLVg_Qc1hZMEFyNWXPrpjjgSkEsO4WHo44BykYfIYuOHWabCIokk3CmcjCRQOY_MbZ181xfklbxV-Vx3U_oAvQK-FPaCC6ySqw52TIpPe-mrKnSiWSXV9g==)\n\nThe combination remains investigational. The companies plan regulatory\ndiscussions and presentation of the findings at a future medical meeting,\nmaking this another development to follow beyond its initial announcement.\nAbbVie News Center\n(https://www.globenewswire.com/Tracker?data=UnydQnZmVi-wfDmXlFqz9NebZOe8mEgm1RRqgwPXAENQ_TbLadZ8RYfDC9G_LqbKO9vJb4NbaaytlxrzsQuPy-UwQpcitMcNwz0C0pygZ0eh5UdmnqnBoNNAuI9aSoj9gFygHuouSKYBf5JFxZ1KEvZesSJQg3h561K8yXTvSssbPJyMi1M0kHEPZ0EhQMQV0WT3-IOyjr5LkU8pjYAw7wrnHsZdd0Eyf3kVawq61ghb3nyjyRNz2HUQpNU-V1f1H6vniwmBjOqVFbBnFQOuF8LJAOAzzDgY05cfc7DIgihzJkhrRUvwtlVa2bP2ccqqrAsWnIPM24hSKw-r-_oNRgsnPh-jPvqfixJGxW4FDoQyDKwEluawXLFermL-Zh3YeSgpCBHSejdLg5KQ65115w==)\n\nTaken together, these developments offer reasons for optimism without\nsuggesting that every clinical question has been answered. An approved\ntherapy, positive randomized trials and an early survival signal occupy\ndifferent positions along the development path. Their shared importance is the\neffort to improve outcomes where existing treatments remain insufficient.\n\nFor NeOnc, the coming months also include a confirmed November 17, 2026, FDA\nEnd-of-Phase 1 meeting for its separate NEO212 program, covering proposed\nclinical-development plans and the evidence needed for a potential future\nmarketing application. That meeting is distinct from NEO100’s development\ndiscussions and does not itself establish an agreed approval pathway. SEC\n(https://www.globenewswire.com/Tracker?data=88WtrAeEBj5wT5Qvsj2itPVwKgaGI4LLIcJdefjGr9WfTydb4fFCEkMBFF9o6wpj81HjNHYplTY-GkRIGbcBcvqCY2EnmAF40oefwUJF3iyI5uTOr9J_WIx5zVgYUD6oPcO0IIhUMg5WvW5ZI8TetbxcqnzhUvSW5iXgK2KZmT4=)\n\nThe hopeful turn in 2026 is not that cancer has been solved. It is that\nseveral approaches are producing evidence worth advancing and, in some cases,\ntreatments patients can already receive.\n\nFor patients and families, the ultimate significance is not a company’s size\nor stock symbol. It is the possibility of more birthdays, more ordinary days,\nand more time together.\n\nAbout 24/7 Market News\n\nIn today's fast-moving markets, visibility is everything and 24/7 Market News\n(24/7) provides a powerful suite of investor relations and public relations\nsolutions designed to elevate your company’s profile quickly and\neffectively. Whether you're an established name seeking broader awareness, or\na micro-cap looking to break out of obscurity, 24/7 delivers targeted,\nhigh-impact coverage through timely news distribution, analyst report\nplacements, featured editorials, and multi-channel amplification across\nfinancial platforms, social media, and investor communities. Our services help\ncut through the noise, attract institutional interest, drive exposure, and\nbuild long-term shareholder credibility, all while maintaining full SEC\ncompliance and transparency. For Analyst Report coverage, custom IR campaigns,\npress release syndication, or other tailored investor and public relations\nsolutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate\nyour company’s visibility and valuation trajectory.\n\nPAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for\ninformational purposes only. 24/7 is compensated by NTHI to provide ongoing\nnews coverage of expected upcoming catalysts and events as well as market\noutreach services. For further disclosure information, please click here\n(https://www.globenewswire.com/Tracker?data=gix6_kz88zn3z61efPIAYcOC-SV8_-7zzj6FKkqFRzS8WWohZBroyxc4tjVol3yLdKSvkeqaPiHIMNNWzR4m2750DSIUzLQg3abQIEHbiYQ=).\nThis should not be construed as financial or investment advice. Trading\ninvolves substantial risk; consult your financial advisor.\n\nImportant Editorial Note: 247 highlights companies approaching significant\ncatalysts and inflection points. This report reflects information available at\nthe time of publication. Since developments can occur rapidly, readers should\nindependently verify current information and review all company filings and\ndisclosures.\n\nCONTACT:\n24/7 Market News\nEditor@247mnn.com\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements that are subject to\nvarious risks and uncertainties. Such statements include statements regarding\nthe Company's ability to grow its business and other statements that are not\nhistorical facts, including statements which may be accompanied by the words\n\"intends,\" \"may,\" \"will,\" \"plans,\" \"expects,\" \"anticipates,\" \"projects,\"\n\"predicts,\" \"estimates,\" \"aims,\" \"believes,\" \"hopes,\" \"potential\" or similar\nwords. Actual results could differ materially from those described in these\nforward-looking statements due to a number of factors, including without\nlimitation, the Company's ability to continue as a going concern, general\neconomic conditions, and other risk factors detailed in the Company's filings\nwith the SEC. The forward-looking statements contained in this press release\nare made as of the date of this press release, and the Company does not\nundertake any responsibility to update such forward-looking statements except\nin accordance with applicable law.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1f91276c-d820-4666-8efc-2d8786490903)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1VBf7f-20261007","title":"NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer","author":"Globe Newswire","ticker":"NTHI","created":"2026-10-07T13:43:54.131Z","tickers":["NTHI"],"exchange":"NASDAQ","article_body":"DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com)-- For\npatients facing cancer, progress ultimately comes down to a deeply personal\nquestion: Can treatment give them more time?\n\nA series of developments reported during 2026 is providing new reasons for\nhope. From an approved treatment for advanced pancreatic cancer to\npersonalized cancer immunotherapy and encouraging survival observations in\nrecurrent brain cancer, publicly traded companies are advancing different\napproaches to some of medicine’s most difficult challenges. These\ndevelopments span different levels of clinical evidence, from exploratory\nPhase 2 findings to randomized Phase 3 results and an FDA approval. SEC\n(https://www.globenewswire.com/Tracker?data=7s-jarmA_Ez5QyKazHtBQNue0KPvJsjcgkPaMFEYpdGhYrtYQbkLFGg_k98hAKweZurACJzEbelLXXYtZp2R6meE3v8wFOu5wldT6ZLyhfYF1JuZ6eRleRno6NVkJeUHSef7Ghq7VRnir_NZd5Haa1JEk4a_1ni0d-BVvx-QOqs=)\n\n24/7 Market News highlights five advances worth following as the year moves\ninto its final quarter, beginning with NeOnc Technologies Holdings and its\nwork in a particularly difficult treatment setting: aggressive brain cancer\nthat has returned after previous therapy.\n\nNeOnc Technologies Holdings (NASDAQ: NTHI): Encouraging Survival Findings\nWhere Better Options Are Urgently Needed\n\nNeOnc stands out in this group for the challenge it is confronting. Recurrent\nhigh-grade brain cancer remains an exceptionally difficult treatment setting.\nThe National Cancer Institute notes that recurrent central nervous system\ntumors are rarely curable, underscoring the importance of developing\nadditional treatment options. Cancer.gov\n(https://www.globenewswire.com/Tracker?data=woZ_YJ3W05l2TPozdw9Z0xMKkDIBOWEH7z4QoZd1ZJwOFD3Zim2SI7CIwKP00uB5fPOrNuGB7KlNre4N4iXbepNFCweiyVTk0CA8z3wYDRkW5vB_u3Zufmkw8Yxy_ybFrcS4sFu4dll4EwT_SetiFA==)\n\nOn August 12, NeOnc reported that patients in its 24-patient Phase 2a study of\nintranasal NEO100 achieved a median overall survival of 26.09 months.\nEstimated survival was 60.9% at 12 months and 54.1% at 24 months. Importantly,\nsurvival was measured from the first treatment dose following recurrence, not\nfrom the original diagnosis. The study involved patients with recurrent or\nprogressive Grade III and Grade IV IDH1-mutant glioma. SEC\n(https://www.globenewswire.com/Tracker?data=nthbVsIQHagvu_IxQOH8TUnfsTh3GPWJIB9c_N26eDKrbb9SfH_oLKPk7RmNBmNed7Ubd0i75jRULnU9zGi8-MV7LQ0zemhS8RtMhWT6J0UFwKzH1ScMA88BqQplJbn4dCH2yOYzrQECLV8jLlXipK_25v1zJWpBnc2I1DQoJmc=)\n\nThe treatment approach is also distinctive. NEO100 is administered\nintranasally by patients at home and is designed to reach the brain through\npathways that bypass the blood-brain barrier, a major obstacle in brain-cancer\ndrug delivery. NeOnc reported predominantly low-grade adverse events and no\nmajor toxicities in the cohort. SEC\n(https://www.globenewswire.com/Tracker?data=mmvm9bW2Ce3AznPsBegRlYUactxVyPeJ9WIeP0SsBrOZsa7_HxXM3kQtbyijXJmIEeBtqdcYWswfIgSpYiOT1hFgnzcE_9p6hG1VHNWar_ZSzhIsAfUPqX6cpZsqf4jlVFtJmSh0HoZyWkU684vqVcX-UqwBNrzIhY5MqwogFH4=)\n\nThese findings represent an encouraging survival signal, not a randomized\ndemonstration of improved survival. The study had no concurrent control group,\nand progression-free-survival findings varied by assessment method, reaching\nstatistical significance against the historical benchmark under RANO 2.0 but\nnot under the original protocol-specified criteria. NeOnc has outlined plans\nto discuss a registrational development pathway with the FDA. SEC\n(https://www.globenewswire.com/Tracker?data=yqGNul-pMhCBs8yCDr1WZYaj-9DsQi7gScyHVLb00vOsAv4e5qv1qlgo7iBokRG0PdOmhzaHsSoOxxeGVeRwoSiEqJ71aA2Wuq3YeLYW2K9iVWGAy_r1YcI7dnW3qGkrfnUj67ITO_lfCTPRqVE_NCZXCSBxin9yokCY9NqJMKo=)\n\nFor a disease setting where treatment options are limited, the combination of\nobserved survival, reported tolerability and an at-home delivery approach\nmakes NEO100 a development worth following as further clinical evaluation\nproceeds. Cancer.gov\n(https://www.globenewswire.com/Tracker?data=woZ_YJ3W05l2TPozdw9Z09EbR0bt3lzmhxWZDOw5vorwUaLtVrYhfVrq0BYr4cz0RKfbv3WVkup9Kz7RoEDQ28a_wvcSFT7c4rVJLgGHnFVjW-aPx_BwmK3TQP7SR4W3OrXWRCMs2q3ZJjiu3mzleA==)\n\nRevolution Medicines (NASDAQ): A Pancreatic-Cancer Advance That Has Already\nReached Approval\n\nRevolution Medicines delivered one of the year’s clearest examples of\nclinical progress translating into an available treatment. On August 26, the\nFDA approved Rasonque, or daraxonrasib, a targeted therapy for metastatic\npancreatic adenocarcinoma. Revolution Medicines\n(https://www.globenewswire.com/Tracker?data=oxa_ZkHAFof5u5n4B5eLrU1MaUoM0bktNicpJdbaFHI6VUGdSmWkO-shcJ4iiN885OkoLB2Xx_sfwg2kGhRAmGQPPZz4NqMskU_7LaTQUr9ttjqac15SR8-V2zYH03dBaNWiyhbpMrGpZSe6Lw5Vqlmzu78yL4ayLaPYRi1KTL9vmNrA-vYQo0gcoC2oZIkNdaqfwnQWBg7HlwQmKalGz45xuS6VMsafZKr1wP7WoVvaG3BZ0VdPcqm7FRMmi9ze)\n\nIn a randomized study involving 500 previously treated patients, median\noverall survival reached 13.2 months with Rasonque versus 6.7 months with\nstandard chemotherapy. Unlike an uncontrolled survival observation, this\nresult established a benefit against a treatment comparator within the same\ntrial. U.S. Food and Drug Administration\n(https://www.globenewswire.com/Tracker?data=9TmfNoC_E_S8Bs-CtCKLhxiqiqI6GXOq0PsqC-0Xk8QpJ6UcYaXcOA2b-NzwRFBlckxMceHiNAXCKxduwQjbswuSAePMklFugyAsleN346Mcx072RiANukCXPuV47RRInJPTtZr1hooJrTJN1qgS43GvP6-8EYYR6uwdZPbbYh6SrhPMQqqFHvMeG5pGD7eHh5T0tZB64q-Q5FZYBrnARl0BcZjBgXJxiCDLo41oHAJqRcZfrkmw9DfHVC_Xbhor)\n\nThe approval is particularly meaningful in pancreatic cancer, where aggressive\ndisease, late detection and historically limited treatment options have\ncontributed to poor outcomes. It also provides a concrete example of what\nsuccessful clinical development can accomplish: moving a promising approach\nfrom research into patient care. U.S. Food and Drug Administration\n(https://www.globenewswire.com/Tracker?data=9TmfNoC_E_S8Bs-CtCKLhxiqiqI6GXOq0PsqC-0Xk8T0nUNatBs04ooC7fisCq3e1lI2KFPQ0zjUo-mJYVr4IMXUtYmgYCBjBrnK5jrV9_l_-h5Ljwx4eE2JGtnkzeU1JoW6v_K3TREJNf-lH9xzIDTgnY0hqNJtmkvfsUm3ehv25dggSJlhLTTbiQV9822vVCioaITJP96NwbrAXf1XpYik4I7h4lZrHqXTSWRF9yiv_bZzopinCuy0teoH7QvK)\n\nModerna (NASDAQ) and Merck (NYSE): Personalized Cancer Immunotherapy Reaches a\nPhase 3 Milestone\n\nModerna and Merck reported a different kind of advance on August 19: positive\nPhase 3 results for intismeran autogene, an individualized mRNA-based cancer\ntherapy, combined with Keytruda.\n\nThe INTerpath-001 trial demonstrated statistically significant improvements in\nrecurrence-free survival and distant-metastasis-free survival compared with\nKeytruda alone in patients whose high-risk melanoma had been surgically\nremoved. According to the companies, this was the first positive Phase 3\nresult for an individualized neoantigen therapy and an mRNA-based cancer\ntreatment. Merck.com\n(https://www.globenewswire.com/Tracker?data=XN3U8SsHvGUJ2EylR72KY5eat3PLMBHn2voYty86vOGbw7XM9ScwFjzAscTo5osOuy1yUydiwOM3l6uaeF61P3zbV9Af7afVr69jEgDbuDq5Tl_HIST9t0LQPTLHbuda6t4zxBiRdrQgNBgnLfxhM2RWk_KT1scjFDyvyI0VSV-tpUsUEKuYdMzBMbv2BlbRpwfDcl5BMEEVJswPt5Ojpx_GnR5tbmyfTKgHRvEHIZL1_JemFjQFoHmwV6T7wV2jCRF9ttYqfEWOwScR_KcXBBtb3X68lR_lWYjzxfTR__wiWHyaIHiWvZjinZbHR3uIWDVolPGCuJI7TFIMKaOPTg==)\n\nThe approach is designed around the characteristics of an individual\npatient’s tumor. Its promise is not a universal vaccine against cancer, but\na more personalized immune response to the disease. Overall-survival follow-up\ncontinues, while the companies plan to engage regulators regarding potential\nsubmissions. Merck.com\n(https://www.globenewswire.com/Tracker?data=XN3U8SsHvGUJ2EylR72KY7_3nSO69ysanpfc6m42Bk3d7Mo2mCuCn44rjXjTmNwpybdL6pKXzEBryAf3VnV41HNg_OwyKZvkQynR6vfNoV35s90Z35oGgY_GYcEfel0J8Oln1ymk9zWSVQDSuTO7GugOPx7yGjWnUjm6ib7fRb5atz6KT7jfRvmPc1WtAcgw83brolH1jbK3-hD-t_v8WuX7rnIY467r_UihkSlWhYtCuFCYW_-c-zWoqT6PUEAes5Ajs7yj4oiATyYPYtO2huAzX7QV0AvAcY9jcB411M7-vllWaBSN5d6wQPuTI4po8v5pLjAv_jLAo-SSqNz_qw==)\n\nJohnson & Johnson (NYSE): Dual-Target Immunotherapy Delivers Substantial\nMyeloma Results\n\nOn July 23, Johnson & Johnson reported that combining Tecvayli and Talvey in\nthe Phase 3 MonumenTAL-6 trial reduced the relative risk of disease\nprogression or death by 89%, and the relative risk of death by 62%, compared\nwith the study’s standard-treatment options.\n\nThe trial involved patients with relapsed or refractory multiple myeloma who\nhad received one to four prior treatment lines. The combination targets two\ndifferent proteins associated with myeloma cells, BCMA and GPRC5D, directing\nimmune activity against the disease through complementary targets. JNJ.com\n(https://www.globenewswire.com/Tracker?data=ixRqyWnoaemxtBuH52lRUFsXADDaHrjzolp4JgbSAIne71lM_I2KnECfRNo2I6GlBwxCmH9Rt2mVY_dSZriwWJDdrtQy6W2yqma1I2J6dgc62ZD74r9hiVrKV5PQnhWxxi-Wa-AyXpDSDqkzjmPnHWQKzzwd7HrpK1qR7THB04I-52mvbx85eqL4uPKJkiULX2Dm9GXrusI_s_FC5Vh2HpNUeFB7QLOqtHHl0s5GHRerp8wy6EE8XjoUy-KwjeQJodL5x6qSAEW-HjXpNSil_Nmn9o1SDNVD2ipBwmTTLJgngTBiZPFen5JwUPUn5bpO)\n\nThe investigational combination’s improvements in both disease control and\noverall survival support the potential to bring this dual-target approach\nearlier into treatment. The reported percentages describe relative reductions\nin risk, not percentages of patients cured. JNJ.com\n(https://www.globenewswire.com/Tracker?data=ixRqyWnoaemxtBuH52lRUFpBWAIdX_TnlPlVKlQWWqXuYoSwteM2i9ACY2PCHMNSxa4DeL_S-78w_yoIckGh-9rYLOqI7wTG2AWPxJ5DgorLmh7aVlXUYr1mWGKBTcjL_Gjg3YDB8k6B1My2x_ncVcFZQPeggnyPe504vKM3jNGIok7iH3O9z_aA1TnjZhvD_N_dUt04kO_X1dj80fRxrtRgqQAlceM0zDDnOpVf9ZnbLeEyW7An4g7ZTk0ivxkJYk-JxCvPo-q4oXzzv-4qpL8Bm0apZgvUfAgsrqicwv4ymSZ0y7assGjxvMSn24SI)\n\nGenmab (NASDAQ) and AbbVie (NYSE): New Hope in First-Line Aggressive Lymphoma\n\nOn October 5, Genmab and AbbVie announced that adding epcoritamab to the\nstandard R-CHOP regimen reduced the relative risk of progression or death by\n51% in the Phase 3 EPCORE DLBCL-2 trial.\n\nThe reported result applied to newly diagnosed diffuse large B-cell lymphoma\npatients with International Prognostic Index scores of 2–5. Its importance\nlies in the possibility of improving treatment at the outset, rather than\nwaiting until the disease returns. AbbVie News Center\n(https://www.globenewswire.com/Tracker?data=UnydQnZmVi-wfDmXlFqz9IKQMehaIH5-KDCh5HG-mkYlecSqWB-2xInn_mEOg0F-wxPanSm7blZs6sEpccewDnkJQZmnRVoP5qdEg78W_5bZckv20Hh5iFtqDwNaR-Bzq7aJQMW4KdfPD4WMDEY3Q0VGmsnP8ZhqtHsjslMHUo1QnbdVGA0HBXEX_QJjoppFQmOnH-XaomC5LL3Urn-aGK4VSbFAYaAJnZoFm3XVIxCPLMbUItCa4nmPQvrAqtOLEGyzF8epaXJ6rrNfyxTxCg84T8MD8fmARLVg_Qc1hZMEFyNWXPrpjjgSkEsO4WHo44BykYfIYuOHWabCIokk3CmcjCRQOY_MbZ181xfklbxV-Vx3U_oAvQK-FPaCC6ySqw52TIpPe-mrKnSiWSXV9g==)\n\nThe combination remains investigational. The companies plan regulatory\ndiscussions and presentation of the findings at a future medical meeting,\nmaking this another development to follow beyond its initial announcement.\nAbbVie News Center\n(https://www.globenewswire.com/Tracker?data=UnydQnZmVi-wfDmXlFqz9NebZOe8mEgm1RRqgwPXAENQ_TbLadZ8RYfDC9G_LqbKO9vJb4NbaaytlxrzsQuPy-UwQpcitMcNwz0C0pygZ0eh5UdmnqnBoNNAuI9aSoj9gFygHuouSKYBf5JFxZ1KEvZesSJQg3h561K8yXTvSssbPJyMi1M0kHEPZ0EhQMQV0WT3-IOyjr5LkU8pjYAw7wrnHsZdd0Eyf3kVawq61ghb3nyjyRNz2HUQpNU-V1f1H6vniwmBjOqVFbBnFQOuF8LJAOAzzDgY05cfc7DIgihzJkhrRUvwtlVa2bP2ccqqrAsWnIPM24hSKw-r-_oNRgsnPh-jPvqfixJGxW4FDoQyDKwEluawXLFermL-Zh3YeSgpCBHSejdLg5KQ65115w==)\n\nTaken together, these developments offer reasons for optimism without\nsuggesting that every clinical question has been answered. An approved\ntherapy, positive randomized trials and an early survival signal occupy\ndifferent positions along the development path. Their shared importance is the\neffort to improve outcomes where existing treatments remain insufficient.\n\nFor NeOnc, the coming months also include a confirmed November 17, 2026, FDA\nEnd-of-Phase 1 meeting for its separate NEO212 program, covering proposed\nclinical-development plans and the evidence needed for a potential future\nmarketing application. That meeting is distinct from NEO100’s development\ndiscussions and does not itself establish an agreed approval pathway. SEC\n(https://www.globenewswire.com/Tracker?data=88WtrAeEBj5wT5Qvsj2itPVwKgaGI4LLIcJdefjGr9WfTydb4fFCEkMBFF9o6wpj81HjNHYplTY-GkRIGbcBcvqCY2EnmAF40oefwUJF3iyI5uTOr9J_WIx5zVgYUD6oPcO0IIhUMg5WvW5ZI8TetbxcqnzhUvSW5iXgK2KZmT4=)\n\nThe hopeful turn in 2026 is not that cancer has been solved. It is that\nseveral approaches are producing evidence worth advancing and, in some cases,\ntreatments patients can already receive.\n\nFor patients and families, the ultimate significance is not a company’s size\nor stock symbol. It is the possibility of more birthdays, more ordinary days,\nand more time together.\n\nAbout 24/7 Market News\n\nIn today's fast-moving markets, visibility is everything and 24/7 Market News\n(24/7) provides a powerful suite of investor relations and public relations\nsolutions designed to elevate your company’s profile quickly and\neffectively. Whether you're an established name seeking broader awareness, or\na micro-cap looking to break out of obscurity, 24/7 delivers targeted,\nhigh-impact coverage through timely news distribution, analyst report\nplacements, featured editorials, and multi-channel amplification across\nfinancial platforms, social media, and investor communities. Our services help\ncut through the noise, attract institutional interest, drive exposure, and\nbuild long-term shareholder credibility, all while maintaining full SEC\ncompliance and transparency. For Analyst Report coverage, custom IR campaigns,\npress release syndication, or other tailored investor and public relations\nsolutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate\nyour company’s visibility and valuation trajectory.\n\nPAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for\ninformational purposes only. 24/7 is compensated by NTHI to provide ongoing\nnews coverage of expected upcoming catalysts and events as well as market\noutreach services. For further disclosure information, please click here\n(https://www.globenewswire.com/Tracker?data=gix6_kz88zn3z61efPIAYcOC-SV8_-7zzj6FKkqFRzS8WWohZBroyxc4tjVol3yLdKSvkeqaPiHIMNNWzR4m2750DSIUzLQg3abQIEHbiYQ=).\nThis should not be construed as financial or investment advice. Trading\ninvolves substantial risk; consult your financial advisor.\n\nImportant Editorial Note: 247 highlights companies approaching significant\ncatalysts and inflection points. This report reflects information available at\nthe time of publication. Since developments can occur rapidly, readers should\nindependently verify current information and review all company filings and\ndisclosures.\n\nCONTACT:\n24/7 Market News\nEditor@247mnn.com\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements that are subject to\nvarious risks and uncertainties. Such statements include statements regarding\nthe Company's ability to grow its business and other statements that are not\nhistorical facts, including statements which may be accompanied by the words\n\"intends,\" \"may,\" \"will,\" \"plans,\" \"expects,\" \"anticipates,\" \"projects,\"\n\"predicts,\" \"estimates,\" \"aims,\" \"believes,\" \"hopes,\" \"potential\" or similar\nwords. Actual results could differ materially from those described in these\nforward-looking statements due to a number of factors, including without\nlimitation, the Company's ability to continue as a going concern, general\neconomic conditions, and other risk factors detailed in the Company's filings\nwith the SEC. The forward-looking statements contained in this press release\nare made as of the date of this press release, and the Company does not\nundertake any responsibility to update such forward-looking statements except\nin accordance with applicable law.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1f91276c-d820-4666-8efc-2d8786490903)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-07T13:43:54.174486986Z","server_sent_at_ms":1791380634174},"received_at":"2026-10-07T13:43:54.342Z","source_url":null},"analysis":{"id":"151719","press_release_id":"163261","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["paid editorial: 24/7 Market News is compensated by NTHI for coverage and market outreach","Phase 2a data uncontrolled; PFS significance dependent on assessment method (RANO 2.0 vs original protocol)","small 24-patient cohort; survival measured post-recurrence","forward-looking statements note going-concern risk"],"eventType":"clinical_trial","narrative":"A paid 24/7 Market News editorial highlights NeOnc Technologies' Phase 2a study of intranasal NEO100 in recurrent Grade III/IV IDH1-mutant glioma, reporting median overall survival of 26.09 months in 24 patients measured from first post-recurrence treatment dose.\n\nThe article stresses the data are an uncontrolled survival signal, not randomized proof, with PFS reaching significance only under RANO 2.0 criteria; NeOnc plans to discuss a registrational pathway with the FDA.\n\nA separate confirmed FDA End-of-Phase 1 meeting for the NEO212 program is set for November 17, 2026.\n\nThe release is a compensated promotional communication and recaps previously disclosed data, so it should be treated as low-signal marketing rather than new issuer news.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Paid promo recap of NEO100 survival signal; watch Nov 17, 2026 NEO212 End-of-Phase 1 FDA meeting instead."},"keyFigures":{"drugName":"NEO100","phaseOfTrial":"Phase 2a","customDimensions":{"patients_enrolled":24,"survival_12mo_pct":60.9,"survival_24mo_pct":54.1,"neo212_eop1_meeting_date":"2026-11-17","median_overall_survival_months":26.09}},"namedEntities":{"people":[],"products":["NEO100","NEO212","Rasonque (daraxonrasib)","intismeran autogene","Keytruda","Tecvayli","Talvey","epcoritamab"],"companies":[{"name":"NeOnc Technologies Holdings","ticker":"NTHI","relationship":"filer/subject"},{"name":"24/7 Market News","relationship":"paid promotional publisher"},{"name":"Revolution Medicines","relationship":"mentioned"},{"name":"Moderna","relationship":"mentioned"},{"name":"Merck","relationship":"mentioned"},{"name":"Johnson & Johnson","relationship":"mentioned"},{"name":"Genmab","relationship":"mentioned"},{"name":"AbbVie","relationship":"mentioned"},{"name":"National Cancer Institute","relationship":"referenced authority"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Third-party paid editorial recap of previously reported Phase 2a NEO100 survival data (median OS 26.09 months in 24 patients) plus a confirmed November 17, 2026 FDA End-of-Phase 1 meeting for NEO212. No new company disclosure, uncontrolled data, and the release is a compensated promotional piece."},"tickerRelevance":{"others":[{"ticker":"MRNA","relevance":"mentioned (Moderna, comparator context)"},{"ticker":"MRK","relevance":"mentioned (Merck, comparator context)"},{"ticker":"JNJ","relevance":"mentioned (Johnson & Johnson, comparator context)"},{"ticker":"RVMD","relevance":"mentioned (Revolution Medicines, comparator context)"},{"ticker":"GMAB","relevance":"mentioned (Genmab, comparator context)"},{"ticker":"ABBV","relevance":"mentioned (AbbVie, comparator context)"}],"primary":"NTHI"},"globalImportance":12,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"novelData":false,"tickerTier":"micro-cap","eventGravity":"paid-editorial-recap","paidPromotion":true,"issuerAuthored":false}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"A paid 24/7 Market News editorial highlights NeOnc Technologies' Phase 2a study of intranasal NEO100 in recurrent Grade III/IV IDH1-mutant glioma, reporting median overall survival of 26.09 months in 24 patients measured from first post-recurrence treatment dose.\n\nThe article stresses the data are an uncontrolled survival signal, not randomized proof, with PFS reaching significance only under RANO 2.0 criteria; NeOnc plans to discuss a registrational pathway with the FDA.\n\nA separate confirmed FDA End-of-Phase 1 meeting for the NEO212 program is set for November 17, 2026.\n\nThe release is a compensated promotional communication and recaps previously disclosed data, so it should be treated as low-signal marketing rather than new issuer news.","key_figures":{"drugName":"NEO100","phaseOfTrial":"Phase 2a","customDimensions":{"patients_enrolled":24,"survival_12mo_pct":60.9,"survival_24mo_pct":54.1,"neo212_eop1_meeting_date":"2026-11-17","median_overall_survival_months":26.09}},"named_entities":{"people":[],"products":["NEO100","NEO212","Rasonque (daraxonrasib)","intismeran autogene","Keytruda","Tecvayli","Talvey","epcoritamab"],"companies":[{"name":"NeOnc Technologies Holdings","ticker":"NTHI","relationship":"filer/subject"},{"name":"24/7 Market News","relationship":"paid promotional publisher"},{"name":"Revolution Medicines","relationship":"mentioned"},{"name":"Moderna","relationship":"mentioned"},{"name":"Merck","relationship":"mentioned"},{"name":"Johnson & Johnson","relationship":"mentioned"},{"name":"Genmab","relationship":"mentioned"},{"name":"AbbVie","relationship":"mentioned"},{"name":"National Cancer Institute","relationship":"referenced authority"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-07T13:44:02.518Z","global_importance":12,"audience_relevance":15,"importance_components":{"novelData":false,"tickerTier":"micro-cap","eventGravity":"paid-editorial-recap","paidPromotion":true,"issuerAuthored":false}},"durationMs":8156,"modelName":"glm-5.3-flashx"}}